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Abstract
Previous studies have shown that the perceptual integration of component motions distributed across space is inhibited
whenever segmentation cues, such as line-ends, are salient. Herein, we investigate to what extent enhanced inhibition induced by
lorazepam, a benzodiazepine facilitating the fixation of GABA on GABAA receptors, modifies the balance between motion
integration and motion segmentation at the behavioural level. Motion integration was tested in 16 healthy volunteers taking a
single and oral dose of either placebo or lorazepam (0.038 mg kg1). The stimulus consisted of an outlined diamond presented
behind four, otherwise invisible, apertures and translating along a circular trajectory (Lorenceau & Shiffrar (1992). Vision
Research, 32, 263–273). Under these conditions, recovering the global diamond direction requires the integration of the
component motions available within each aperture. The observers were asked to discriminate the global, clockwise or
counter-clockwise, diamond direction under difficult—at high luminance contrasts—or easy—at low luminance contrasts—con-
ditions. Overall, reaction times and error rates increased in the lorazepam group as compared to the placebo group, suggesting
strong non-specific effects. However, the changes in performance in the lorazepam group are not homogeneous across conditions,
suggesting that lorazepam also induces specific effects that modulate the integration:segmentation balance. Additional experiments
performed with visible apertures or visible diamond vertices indicate that the effects of lorazepam are unlikely to reflect a deficit
of motion processing or motion integration mechanisms since performance is only slightly impaired in the lorazepam as compared
to the placebo group under these conditions. These results suggest that lorazepam might specifically modulate the saliency of
line-ends, presumably because processing these features involves inhibitory mechanisms using GABA as a neuromediator, and in
turn modify the balance between motion integration and segmentation. © 1999 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The use of benzodiazepines such as lorazepam is
widespread in many countries. Although the mecha-
nisms by which lorazepam acts on the central nervous
system are known to involve the GABA neurotransmit-
tor, which largely contributes to visual processing at
various stages (Bolz & Gilbert, 1986; Norton & God-
win, 1992; Sillito, 1992; Morin & Molotchnikoff, 1994),
the effects of lorazepam at the perceptual level have not
been thoroughly studied. The target of lorazepam is the
benzodiazepine fixation site which is part of the
GABAA receptors. Lorazepam has no effect on
GABAB or GABAC receptors. Moreover, it has no
direct effect on the GABA receptor but acts only in the
presence of GABA and potentiates its effect (Hill &
Bowery, 1981; Drew, Johnston & Wheatherby, 1984;
Johnston, 1994; Mohler, Benke, Benson, Lu¨scher &
Fritschy, 1995; Smith & Olsen, 1995).
In the present study, we used lorazepam in a neu-
ropsychological-like approach to dissociate the different
effects of lorazepam on visuo-perceptual processes.
Given the relative specificity of the pharmacological
action of lorazepam, this approach may provide in-
sights into the functional role of GABAA connections
at the behavioural level and help to relate electrophysi-
ological studies to perceptual processes.* Corresponding author. E-mail: giersch@alsace.u-strasbg.fr.
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This approach has already been used to dissociate the
different effects of lorazepam on sedation, on the pro-
cessing of spatial frequencies, on contour integration or
attentional processes (Giersch, Boucart, Speeg-Schatz,
Muller-Kauffmann & Danion, 1996; Giersch, Boucart
& Danion, 1997). It was discovered that perceptual
tasks requiring the integration of contours from static
stimuli like fragmented, compound letters or frag-
mented pictures, are particularly affected by lorazepam
(Giersch, Boucart, Danion, Vidailhet & Legrand, 1995;
Giersch et al., 1996, 1997; Giersch (in press)). The
results from these studies were consistent with the
hypothesis that lorazepam acts by facilitating the pro-
cessing of segmentation cues, such as line-ends. Herein,
we attempt to generalize these findings to determine to
what extent the balance between motion integration
and motion segmentation is affected by lorazepam.
Indeed, recovering the motion of objects requires that
the local responses from cortical neurons to an input
image are bounded together. Although the distributed
architecture of the primary visual cortex calls for inte-
gration processes, spurious associations between fea-
tures belonging to different objects must also be
avoided, implying that segmentation processes are also
involved. It has been argued that both processes work
in a cooperative:competitive way (Grossberg & Min-
golla, 1985; Peterhans & von der Heydt, 1989; Heitger,
Rosenthaler, von der Heydt, Peterhans & Kubler, 1992;
Gove, Grossberg & Mingolla, 1995) and heavily rely on
line-ends processing (Shimojo, Silverman & Nakayama,
1989; Lorenceau & Shiffrar, 1992).
Experimental evidence (Biederman, 1987; Shimojo et
al., 1989; Bregman, 1990; Shimojo & Nakayama, 1990;
Lorenceau & Shiffrar, 1992; Stoner & Albright, 1992)
suggests a straightforward distinction between features
produced by accidental occlusion and features that
intrinsically belong to objects (Fig. 1). The former do
not intervene in visual segmentation whereas the latter
signal real contour discontinuities and strongly con-
strain the parsing of the retinal image into distinct
entities (Nakayama, Shimojo & Silverman, 1989;
Stoner, Albright & Ramachandran, 1990).
To determine whether lorazepam influences the inte-
gration and segmentation of component motions, we
used aperture stimuli and manipulated the status, ex-
trinsic or intrinsic, of line-ends that occur at apertures’
Fig. 2. A diamond seen through four, otherwise invisible, rectangular
apertures translates along a circular path in a clockwise or counter
clockwise direction, such that only four line-segments are visible. Two
frames of an animation sequence are shown. Integrating motion
components are required to recover the global diamond’s direction.
borders. Using this class of stimuli, Lorenceau and
Shiffrar (1992) found that motion integration is easy
whenever the line-ends are extrinsic or when their
salience is reduced (e.g. at low luminance). On the other
hand motion integration is difficult whenever the line-
ends are intrinsic (e.g. when the apertures are invisible).
In the present experiments, we used a display consist-
ing of a diamond outline visible through four invisible
stationary apertures such that the diamond’s edges were
visible, but its corners were hidden. Under these condi-
tions, a circular motion -clockwise or counter-clockwise
of the diamond results in local segments motions which
may differ from the global motion. In particular, the
motion of line-ends at aperture borders, straight and
parallel to the borders, is inconsistent with the clock-
wise or counter-clockwise diamond trajectory (Fig. 2).
Lorazepam could affect motion integration perfor-
mance in a variety of ways: it could decrease contrast
sensitivity (Harris & Phillipson, 1995) or impair eye
movements (Fafrowicz, Unrug, Marek, van Luijtelaar,
Noworol & Coenen, 1995; Hopfenbeck, Cowley,
Radant, Greenblatt & Roy-Byrne, 1995). Benzodi-
azepines might also affect the processing of orientation
or direction (Sillito, 1975; Berman, Douglas & Martin,
1992; Bradley, Qian & Andersen, 1995; Somers, Nelson
& Sur, 1995). Note that these different potential effects
are non-specific, in the sense that they should affect
similar experimental conditions that yield easy or
difficult motion integration. To isolate a specific effect
of lorazepam on motion integration, one must ensure
Fig. 1. Examples of intrinsic line-ends (on the left) and extrinsic
line-ends with T occlusions (on the right).
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Fig. 3. (a) In the ‘invisible apertures’ experiment, the four apertures are arranged so that only four gray line-segments are visible on the black
background. (b) In the ‘visible corners’ experiment, the four sides are masked and only the corners are visible. (c) In the ‘visible apertures’, the
four apertures again mask the corners but are visible. Four gray line-segments are seen through four black apertures, displayed against a grey
background.
that non-specific effects of lorazepam are negligible or
use an experimental design that permits comparisons
between a reference baseline and test conditions. We
adopted the following experimental strategy: firstly, we
measured absolute detection thresholds and motion
coherence thresholds before and after lorazepam up-
take. The former permits one to determine whether the
visibility of the stimuli is affected by the intake of
lorazepam. The measure of coherence thresholds—the
highest contrast which still induces a coherent per-
cept—permits one to estimate the effect of lorazepam
on motion integration. If both thresholds are similarly
affected by lorazepam, this would suggest that coher-
ence thresholds depend upon contrast sensitivity. If on
the other hand both thresholds are differently affected
this would suggest that lorazepam has a specific influ-
ence on motion integration. Secondly, we used a 2AFC
procedure to measure direction discrimination perfor-
mance as a function of luminance contrast, using a
short duration of motion. Indeed, previous studies
demonstrated that simple contrast manipulations
deeply change motion interpretation while maintaining
the same retinal motion. If lorazepam impairs fixation
or eye movements, performance should be similarly
affected under the different contrast conditions, while a
specific influence of lorazepam should differentially
modify performance. We also measured direction dis-
crimination using a diamond with visible corners which
provides a reference baseline to estimate the non-spe-
cific influences of lorazepam on performance (Fig. 3).
Under these new conditions, the integration of compo-
nent motion across space is not required to perform the
task since the motion of a single corner is sufficient to
determine the diamond’s direction. If lorazepam im-
pairs the processing of direction, lorazepam-treated
subjects should be impaired in all conditions. Finally,
we used a diamond moving behind visible apertures
(Fig. 3). Changing aperture visibility shifts the status of
line-ends from intrinsic to extrinsic. If motion integra-
tion processes are affected, performance should also be
impaired when the apertures are visible, since the inte-
gration of component motions is necessary to perform
the task under these conditions. In contrast, if lo-
razepam specifically modulates the contribution of in-
trinsic line-ends to the integration and segmentation of
local motion, there should be no degradation of perfor-
mance at high luminance in lorazepam-treated subjects,
since extrinsic line-ends are thought to be discarded
from the integration processes (Shimojo et al., 1989).
2. General methods
2.1. Subjects
In total 16 healthy volunteers (11 women and 5 men)
were recruited in the University of Strasbourg. The
protocol was approved by the Faculty Ethics Commit-
tee. All subjects gave their written informed consent.
They were paid 1000FF for their participation.
The subjects had no medical illness or history of
alcoholism, drug abuse or tobacco consumption of
more than ten cigarettes per day. They were not chronic
users of benzodiazepines and had not taken any medi-
cation for at least 15 days. They were instructed to
abstain from beverages containing caffeine or alcohol
for the 24 h prior to the study. The drug was adminis-
tered to the subjects in the morning, after an overnight
fast.
2.2. Experimental design and drugs
Subjects were randomly assigned to one of two paral-
lel groups, of eight subjects each: a placebo group and
a lorazepam (0.038 mg kg1) group. The drug capsule
was given orally using a double-blind procedure. The
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experiments were conducted the day before the intake
of the drug and subjects were investigated again be-
tween 1.3 and 3 h after the intake of the placebo or
lorazepam capsule. All subjects were tested with opti-
cal correction. The presentation of the stimuli was
always monocular to avoid any contamination of the
results by a lorazepam induced impairment of the ocu-
lomotor balance (lorazepam does not affect visual acu-
ity nor accommodation; Giersch et al., 1996).
2.3. Apparatus and stimuli
The stimuli were displayed on a 21% colour video
monitor (IDEK 53021). They were generated through
a micro-computer equipped with a GEMINI graphic
card. The screen resolution was 10241280 pixels (60
Hz, 8 bit:pixel). The viewing distance was 114 cm.
Subjects had their head maintained by a chin rest with
a forehead support and gave their response by press-
ing the right or left arrow of the computer keyboard.
The stimulus was a centrally displayed diamond
(whose side length was 3.8° of visual angle) translating
in a clockwise or counter-clockwise direction along a
circular path (path radius of 0.3°). A central red fixa-
tion point was present throughout the experiments.
The trajectory starting point was randomly chosen
among eight possibilities, separated by 45° steps. The
direction of translation, either clockwise or counter-
clockwise was randomly chosen on each trial. The
inter-trial interval was fixed at 1000 ms after the exe-
cution of the response.
During the threshold measurements, the diamond,
whose luminance was chosen at random, moved con-
tinuously along a circular trajectory. It was visible
through four invisible squared apertures (1.31.3° of
visual angle) and only four straight edges of the dia-
mond were visible. Since background luminance was
kept at 0.02 cd m2, contrast increased with increas-
ing diamond luminance. The subjects used the right
and left mouse buttons to adjust the luminance, either
to just detect the presence of a stimulus, independently
of its motion, or to determine the maximum lumi-
nance which yields a coherent motion (i.e. higher lumi-
nance would result in incoherent segment motion).
When the subjects were satisfied with their settings, the
response was recorded and the stimulus was cleared.
Measures were repeated 20 times.
In 2AFC experiments, the diamond translated along
a circular path for 150 ms (about 1:6 of a cycle). On
each trial, the diamond’s luminance (1, 1.5, 3, 6, 12.5,
and 25 cd m2) was chosen at random. Each experi-
ment included a total of 240 trials (40 trials per condi-
tion) in two blocks of 120 trials. The subjects,
informed that the four visible elements were part of a
diamond, were instructed to discriminate the global
diamond’s direction -clockwise or counter-clockwise
and to respond as accurately and rapidly as possible
by pressing on the right or left arrow of the keyboard.
No feedback was given to the subjects during the
experiments. (1) When apertures were invisible and
masked the corners of the diamond, only straight line-
segments moved against a dark background (0.02 cd
m2) (‘invisible apertures’ experiment). (2) The ‘visible
corners’ experiment differed from the ‘invisible aper-
tures’ experiment in that the four static apertures
masked the sides of the moving diamond. Only the
diamond corners were visible. (3) The ‘visible aper-
tures’ experiment differed from the ‘invisible apertures’
experiment in that four dark apertures (luminance 0.02
cd m2) were presented against a grey background (1
cd m2) (Fig. 3).
2.4. Procedure
The subjects started with a training session the day
before the intake of the placebo or lorazepam capsule.
They had to decide whether a diamond, whose corners
were visible, moved clockwise or counter-clockwise.
The practice session was stopped when performance
was higher than or equal to 75% correct response at
the end of a block of 40 trials. Subjects had then
performed a complete experimental session, which was
repeated on the day of the capsule intake. In the two
experimental sessions, each experiment was preceded
by a 20 trials training session. The order of the experi-
ments was randomized across subjects in each treat-
ment group, but was the same for each subject before
and after the intake of the placebo or lorazepam cap-
sule.
2.5. Analogue self-ratings of sedation
Subjects assessed their subjective feelings before and
1.5 h after the intake of the placebo or lorazepam
capsule. They used a set of 15 visual analogue scales
derived from Bond and Lader (1974). Each scale con-
sisted of a 100 mm horizontal line without gradation,
anchored by contrasting states of mind. Subjects were
asked to regard each line as a continuum and to rate
their feelings by placing a vertical mark across each
line. The ratings were measured as the distance in
millimetres between the positive end of each line and
the subject’s mark. Five scales were used to assess
complementary aspects of sedation (alert–drowsy, ex-
cited–calm, clear headed–muzzy, energetic–lethargic,
fast–slow). The mean score of these five scales was
calculated for each subject, before and after the intake
of the drug. A sedation index was calculated by divid-
ing the difference in scores observed before and after
the intake of placebo or lorazepam by the score ob-
served before the intake of the drug capsule.
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2.6. Analysis of results
No difference in performance was observed between
treatment groups before the intake of the placebo or
lorazepam capsule. The results observed before treat-
ment reproduced those published in Lorenceau and
Shiffrar (1992). We shall hence focus our analysis on the
comparison of performance before and after the intake
of the drug capsule in the two treatment groups.
As lorazepam has sedative effects, some lorazepam-
treated subjects had temporary lapses in vigilance. The
frequency of these lapses was between 0 and 10 in one
experiment, depending on the lorazepam-induced seda-
tion. These lapses induced increased RTs. Hence, we
discarded the highest RTs in the results, so that less than
2% of the data were discarded in the lorazepam group.
3. Results
3.1. Detection and coherence thresholds
Analyses of variance were conducted on the detection
thresholds and on the coherence thresholds, with subjects
as a random variable. There was one between-subject
variable, the treatment, and one within-subject variable,
the day of test (before or after treatment). The results,
averaged over subjects and direction of motion, are
displayed in Fig. 4.
Before treatment, the averaged detection threshold is
0.18 cd m2 (90.05 SD) and the coherence threshold
is 0.67 cd m2 (90.59 SD). After the intake of the drug,
the detection threshold increases by 0.09 cd m2 in the
lorazepam group (F [1, 7]8, PB0.05) and decreases by
Fig. 5. Correct RTs (upper panels) and errors (lower panels) for each
subject in the lorazepam group, in the invisible apertures experiment,
before the intake of the drug (left) or after the intake of the drug
(right) as a function of the luminance levels (1, 1.5, 3, 6, 12.5 or 25 cd
m2). Each data point represents the mean of 40 measures for one
subject.
Fig. 4. Detection (black bars) and coherence (white bars) thresholds
averaged across observers, before and after treatment, in the placebo
and the lorazepam (0.038 mg kg1) group. Each column represents
the mean of 20 measures for the eight subjects of each group.
0.01 cd m2 in the placebo group (FB1). In contrast,
the coherence threshold remains stable in the two groups
(FB1).
3.2. 2AFC Experiments
Individual results in the ‘invisible apertures experi-
ment’ are displayed Fig. 5. As a general trend the error
rate increases as the luminance of the segments increases,
which replicates previous results (Lorenceau & Shiffrar,
1992). Analyzing individual results indicates that all
subjects are impaired at high luminance after the intake
of lorazepam whereas an impairment at low luminance
is observed in only two subjects.
These two subjects respond at chance level when the
diamond’s luminance is 1 cd m2 (above 60% errors vs.
errors lower than 35% at medium luminance), whereas
the other subjects make no more than 25% errors at 1
cd m2. The same two subjects are also those showing
the highest detection threshold in the adjustment
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experiment (0.38 and 0.37 cd m2 vs. a mean of 0.22 cd
m2 in the other subjects—from 0.15 to 0.29 cd m2).
Since the duration of motion is only 150 ms in the
present experiment it is likely that the lowest luminance
levels (1 and 1.5 cd m2) were close or below the
detection threshold of these two observers.
At high luminance, these same two subjects made
many errors and their RTs were much longer than
those of the other subjects. We thus discarded the
results of these two subjects from the analysis to ensure
that the results observed at high luminance are not
simply due to the results of these two observers. How-
ever, it is worth noting that all significant effects de-
scribed in the following three experiments are also
significant when all subjects are included in the analysis
and only the four highest luminance levels are
considered.
Analyses of variance were conducted on RTs and
errors, with subjects as a random variable. The differ-
ential results (after vs. before the intake of the drug) of
the six remaining subjects are displayed Fig. 6 for each
2AFC experiment.
Before treatment, the mean RTs and the mean error
rate across groups and experiments are respectively 881
ms and 7%. In the placebo group, RTs and the error rate
decrease on the following day (by 100 ms, F [1, 7]21.5,
PB0.005, and by 1.3%, F [1, 7]1.7, ns). These changes
in performance are likely to be explained by an effect of
practice and may reflect some form of perceptual learn-
ing. Such effect of practice has already been observed in
similar experiments (Lorenceau, 1996). In contrast, RTs
and errors increase in the lorazepam group on the
following day (by 192 ms, F [1, 5]29.2, PB0.005, and
by 8.1%, F [1, 5]21.9, PB0.01).
Although lorazepam globally degrades performance,
either RTs or error rates, this degradation is not
equally distributed among the different experimental
conditions, and seems to depend on the segment lumi-
nance, at least for RTs, as suggested by a significant
interaction between the treatment, the diamond lumi-
nance, the type of experiment and the day of test-before
or after treatment—(F [10, 120]2, PB0.05 for RTs).
Further analyses show that this interaction results from
the fact that, after the intake of lorazepam, RTs in-
crease more with luminance in the ‘invisible apertures’
experiment (black circles) than in the two other experi-
ments. Indeed, in the ‘invisible apertures’ experiment,
RTs increase significantly with increasing luminance
only after the intake of lorazepam (102 ms, F [5,
25]4.7, PB0.005), in a linear way (polynomial test
of order 1: F [1, 5]16.9, PB0.01; RTs increase by 43
ms from 1 to 6 cd m2, F [1, 5]9.2, PB0.05). RTs do
not increase significantly with luminance in the placebo
group (60 ms before treatment, F [5, 35]1.4, ns and
1 ms after treatment, FB1) nor in the lorazepam group
before the intake of the drug (16 ms, FB1). In the
two other experiments, the changes in RTs across ex-
perimental sessions did not vary significantly with lumi-
nance between the two groups1 (FsB1.4). In addition,
Fig. 6. Mean RTs (upper panel) and errors (lower panel) differences
between the two experimental sessions (before and after the intake of
the drug) with standard errors (averaged across subjects) as a func-
tion of the type of stimulus, line-segments in invisible apertures (black
circles), visible apertures (white squares), or visible corners (white
diamonds) for six luminance levels (1, 1.5, 3, 6, 12.5 or 25 cd m2),
in the placebo group (dashed lines) and in the lorazepam group (plain
lines). Each data point represents the mean of 40 measures for eight
subjects in the placebo group and six subjects in the lorazepam group.
1 In Fig. 6, the change in RT after the intake of lorazepam appears
to increase slightly with luminance in the ‘visible corners’ experiment.
However, that was due to the results of one subject only. All other
subjects had perfectly flat curves. Concerning the ‘visible apertures’
experiment, the degradation of performance apparent on the graphic
at low luminance was not significant for RTs and only tended to be
significant for errors (F [5, 25]2.5, P0.057). The changes in RTs
at low luminance probably plays only a minor role in the fourth order
interaction. This conclusion is supported by the sub-analysis showing
that the slope fitted to the data of the lorazepam group (using data
from 12.5 and 25 cdm2 from the ‘invisible apertures’ experiment) is
steeper than the slope observed in the ‘visible corners’ experiment
(F [1,5]8.4, PB0.05) and in the ‘visible apertures’ experiment
(F [1,5]8.3, PB0.05).
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the increase of error rates induced by lorazepam is larger
in the ‘invisible apertures’ experiment than in the two
other experiments. This results in a significant interaction
between the treatment, the type of experiment and the
day of test (F [2, 24]8.2, PB0.005). Consistent with
the RT results, this effect is significant at the highest
luminance (from 3 to 25 cd m2) in the lorazepam group
(14.6% in the ‘invisible apertures’ experiment vs.
3.8% in the two other experiments, F [2, 10]7.5,
PB0.01), but not at the lowest contrasts (1 and 1.5 cd
m2) (13.1% in the ‘invisible apertures’ experiment vs.
8% in the two other experiments, FsB2.2).
A correlation analysis showed that the increase in the
detection threshold is significantly correlated with the
sedation index in the lorazepam group (r0.753, N8,
PB0.05). There is no significant correlation between the
sedation index and the performance impairment induced
by lorazepam at high luminance, even when all eight
subjects are included (Pearson correlation, coefficients
rB0.27).
4. General discussion
Using a double blind procedure, we measured the
effects of an uptake of lorazepam on performance in a
motion integration task. The results can be summarized
as follows:
(1) Contrast thresholds for the detection of the dia-
mond stimulus increase under lorazepam conditions,
consistent with previous data (Harris & Phillipson,
1995). This effect is positively correlated with the seda-
tion index. (2) Despite increased detection thresholds, the
contrast thresholds for global coherence are stable under
lorazepam conditions. (3) Lorazepam induces an in-
crease in both RTs and errors in the direction discrimi-
nation experiments. (4) The performance degradation in
the lorazepam group is larger in the ‘invisible apertures’
experiment than in the ‘visible apertures’ and ‘visible
corners’ experiments. These effects are significant at
high, but not at low luminance contrasts.
Several aspects of the present results suggest that the
effects of lorazepam are different at low and high
luminance contrasts. Firstly, sedation is correlated with
the increase in the detection threshold, but not with the
degradation of performance at high luminance. Sec-
ondly, the decrease in performance observed at low
luminance is not significantly different across experi-
ments. That lorazepam decreases contrast sensitivity
(Blin, Mestre, Paut, Vercher & Audebert, 1993; Mad-
dock, Casson, Lott, Carter & Johnson, 1993; Harris &
Phillipson, 1995), suggests that impaired performance at
low luminance contrasts results from decreased stimulus
visibility. According to Maddock et al. (1993), the effects
observed at low luminance would be non-specific, and
related to the sedative effect of lorazepam.
At high luminance, the increase in RTs is significantly
larger in the ‘invisible apertures’ experiment than in the
other experiments. This effect, which does not result
from a speed-accuracy trade-off, is incompatible with the
idea that non-specific effects of lorazepam on eye move-
ments, fixation, direction or orientation processing are
involved. One might argue that the task is more difficult
at high luminance in the ‘invisible aperture’ experiment,
and that the performance degradation in these condi-
tions is due to a sedative effect. However, the effect
persists even when the more sedated subjects are dis-
carded from the analysis. The amplitude of the remaining
effect (102 ms) can hardly been explained by a simple
sedative effect. Moreover, additional experiments which
involve experimental conditions of similar difficulty
(Giersch (in press); Lorenceau & Giersch (in prepara-
tion)) suggest, that the performance degradation induced
by lorazepam is not necessarily related to the difficulty
of the task. Finally, the hypothesis that motion integra-
tion processes are specifically affected can also be ruled
out. Indeed, integrating component motions—and thus
recovering the local component direction and speed—is
necessary to perform the task in the ‘visible apertures’
experiment. However, direction discrimination perfor-
mance is slightly less impaired at high luminance than at
low luminance under these conditions and is similar to
that of the ‘visible corners’ experiment that does not
require the integration of component motions across
space. Since the main difference between the ‘visible’ and
‘invisible’ apertures conditions lies in the status of the
line-ends, extrinsic in the former, intrinsic in the latter,
one possible explanation of these effects is that lo-
razepam specifically affects the processing of intrinsic
line-ends. This hypothesis is compatible with the results
from previous experiments using static collinear elements
suggesting that lorazepam improves the detection of
spatial discontinuities (Giersch et al., 1995, 1996, 1997;
Giersch (in press)).
With the assumption that lorazepam specifically af-
fects performance in perceptual integration tasks
through modulations of line-end salience, it remains to
be determined what could be the physiological substrate
of these effects. Although numerous physiological stud-
ies stressed the fact that lorazepam facilitates the fixation
of GABA on the GABAA receptor and emphasized the
role of GABA in visual processing, a discussion of the
present results at the light of these physiological studies
can only be highly speculative.
One possibility is that end-stopped or hypercomplex
cells, commonly found in cat and monkey visual cortex,
(Hubel & Wiesel, 1968; Saito, Tanaka, Fukada & Oya-
mada, 1988; von der Heydt & Peterhans, 1989) are
involved. As a matter of fact, these cells respond opti-
mally to short bars or spatial discontinuities and have a
poor contrast sensitivity (Hubel & Wiesel, 1965; Orban,
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Kato & Bishop, 1979a,b; Duysens, Orban, van der
Glas & De Zegher, 1982a; Duysens, Orban, van der
Glas & Maes, 1982b; Tanaka, Ohzawa, Ramoa &
Freeman, 1987; Saito et al., 1988; Jagadeesh & Fer-
ster, 1990; DeAngelis, Freeman & Ohzawa, 1994). In
addition, GABA is likely to be involved in the gener-
ation of end-inhibition, as intravenous bicuculline (a
GABAA antagonist) induces an extinction of the end-
inhibition properties of hypercomplex cells in the cat
(Pettigrew & Daniels, 1973; Rose & Blakemore,
1974).
The hypothesis of a role of end-stopped cells to
account for the effects presented herein offers the ad-
vantage of a great consistency between the existing
physiological literature and our results. However, one
cannot exclude other alternative explanations. Lo-
razepam may increase the weight accorded to the
line-ends, or induce an imbalance between discontinu-
ous information and continuous information, but af-
ter the processing of line-ends has been carried out.
Further electrophysiological studies are needed to dis-
tinguish between these hypotheses.
Whatever the precise processing level affected by
lorazepam, it is worth noting that although treated
subjects are slowed down, they still perform accu-
rately in the motion integration task, suggesting that
lorazepam does not induce a visual deficit but rather
a modulation in the processing of visual information.
A modulatory effect is consistent with a hypothesis in
terms of an imbalance between either the processing
or the use of discontinuous and continuous informa-
tion, at the cost of continuous information.
5. Conclusion
Our results, consistent with previous experiments,
suggest that lorazepam enhances the processing of
line-ends which in turn impairs the integration of
component motions across space. As lorazepam has
both an effect on the fixation of GABA on the
GABAA receptor and at the behavioral level, we sug-
gest that lorazepam might be used in a neuropsycho-
logical-like approach to dissociate the different
processes involved in the analysis of sensory informa-
tion and to establish links between electrophysiology
and experimental psychology.
Acknowledgements
This work was supported by the University Hospi-
tal of Strasbourg and by INSERM. The authors
thank M. Welsch for medical examination of the
healthy volunteers.
References
Berman, N. J., Douglas, R. J., & Martin, K. A. C. (1992). GABA-
mediated inhibition in the neural networks of visual cortex.
Progress in Brain Research, 90, 443–476.
Biederman, I. (1987). Recognition-by-components: a theory of human
image understanding. Psychological Re6iew, 94, 115–147.
Blin, O., Mestre, D., Paut, O., Vercher, J. L., & Audebert, C. (1993).
GABA-ergic control of visual perception in healthy volunteers:
effects of midazolam, a benzodiazepine, on spatio–temporal con-
trast sensitivity. British Journal of Clinical Pharmacology, 36,
117–124.
Bolz, J., & Gilbert, C. D. (1986). Generation of end-inhibition in the
visual cortex via interlaminar connections. Nature, 320, 362–365.
Bond, A., & Lader, M. (1974). The use of analogue scales in rating
subjective feelings. British Journal of Medical Psychology, 47,
211–218.
Bradley, D. C., Qian, N., & Andersen, R. A. (1995). Integration of
motion and stereopsis in middle temporal cortical area of
macaques. Nature, 373, 609–611.
Bregman, S. (1990). Auditory scene analysis. The perceptual organiza-
tion of sound. Cambridge, MA: MIT Bradford books.
DeAngelis, G. C., Freeman, R. D., & Ohzawa, I. (1994). Length and
width tuning of neurons in the cat’s primary visual cortex. Journal
of Neurophysiology, 71, 347–374.
Drew, C. A., Johnston, G. A. R., & Wheatherby, R. P. (1984).
Bicuculline-insensitive GABA receptors: studies on the binding of
(-)-baclofen to rat cerebellar membranes. Neuroscience Letters, 52,
317.
Duysens, J., Orban, G. A., van der Glas, H. W., & De Zegher, F. E.
(1982). Functional properties of area 19 as compared to area 17 of
the cat. Brain Research, 231, 279–291.
Duysens, J., Orban, G. A., van der Glas, H. W., & Maes, H. (1982).
Receptive field structure of area 19 as compared to area 17 of the
cat. Brain Research, 231, 293–308.
Fafrowicz, M., Unrug, A., Marek, T., van Luijtelaar, G., Noworol,
C., & Coenen, A. (1995). Effects of diazepam and buspirone on
reaction time of saccadic eye movements. Neuropsychobiology, 32,
156–160.
Giersch, A., Boucart, M., Danion, J. M., Vidailhet, P., & Legrand, F.
(1995). Effects of lorazepam on perceptual integration of visual
forms in healthy volunteers. Psychopharmacology, 119, 105–114.
Giersch, A., Boucart, M., Speeg-Schatz, C., Muller-Kauffmann, F., &
Danion, J. M. (1996). Lorazepam impairs perceptual integration
of visual forms: a central effect. Psychopharmacology, 126, 260–
270.
Giersch, A., Boucart, M., & Danion, J. M. (1997). Lorazepam, a
benzodiazepine, induces atypical distractor effects with compound
stimuli: a role for line-ends in the processing of compound letters.
Visual Cognition, 4, 337–372.
Giersch, A. (in press) A new pharmacological tool to investigate
integration processes. Visual Cognition, special issue.
Gove, A., Grossberg, S., & Mingolla, E. (1995). Brightness percep-
tion, illusory contours, and corticogeniculate feedback. Visual
Neuroscience, 12, 1027–1052.
Grossberg, S., & Mingolla, E. (1985). Neural dynamics of perceptual
grouping: textures, boundaries, and emergent segmentations. Per-
ception & Psychophysics, 38, 141–171.
Harris, J. P., & Phillipson, O. T. (1995). Effects of lorazepam on
human contrast sensitivity. Psychopharmacology, 117, 379–384.
Heitger, F., Rosenthaler, L., von der Heydt, R., Peterhans, E., &
Kubler, O. (1992). Simulation of neural contour mechanisms:
from simple to end-stopped cells. Vision Research, 32, 963–981.
Hill, D. R., & Bowery, N. G. (1981). 3H-Baclofen and 3H-GABA
bind to bicuculline-insensitive GABAB sites in rat brain. Nature,
361, 149–152.
A. Giersch, J. Lorenceau : Vision Research 39 (1999) 2017–2025 2025
Hopfenbeck, J. R., Cowley, D. S., Radant, A., Greenblatt, D. J., &
Roy-Byrne, P. P. (1995). Effects of diphenhydramine on human
eye movements. Psychopharmacology, 118, 280–286.
Hubel, D. H., & Wiesel, T. N. (1965). Receptive fields and functional
architecture in two nonstriate visual areas (18 and 19) of the cat.
Journal of Neurophysiology, 28, 229–289.
Hubel, D. H., & Wiesel, T. N. (1968). Receptive fields and functional
architecture of the monkey striate cortex. Journal of Physiology
(London), 195, 215–243.
Jagadeesh, B., & Ferster, D. (1990). Receptive field lengths in cat
striate cortex can increase with decreasing stimulus contrast.
Society for Neuroscience (Abstracts), 16, 293.
Johnston, G. A. R. (1994). GABAC receptors. Progress in Brain
Research, 100, 61–65.
Lorenceau, J., & Shiffrar, M. (1992). The influence of terminators of
motion integration across space. Vision Research, 32, 263–273.
Lorenceau, J. (1996). Motion integration with dot patterns: effects of
motion noise and structural information. Vision Research, 36,
3415–3427.
Lorenceau, J., & Giersch, A. (in preparation). Delayed access to
moving features in pseudo-collinear displays.
Maddock, R. J., Casson, E. J., Lott, L. A., Carter, C. S., & Johnson,
C. A. (1993). Benzodiazepine effects on flicker sensitivity: role of
stimulus frequency and size. Progress in Neuro-Psychopharmacol-
ogy and Biological Psychiatry, 17, 955–970.
Mohler, H., Benke, D., Benson, J., Lu¨scher, B., & Fritschy, J. M.
(1995). GABAA-receptor subtypes in vivo: cellular localization,
pharmacology and regulation. In G. Biggio, E. Sanna, & E.
Costa, GABAA receptors and anxiety: From neurobiology to treat-
ment (pp. 41–56). New York: Raven Press.
Morin, C., & Molotchnikoff, S. (1994). Influences of horizontal
connections on visual responses in rabbit striate cortex. European
Journal of Neuroscience, 6, 1063–1071.
Nakayama, K., Shimojo, S., & Silverman, G. H. (1989). Stereoscopic
depth: its relation to image segmentation, grouping, and the
recognition of occluded objects. Perception, 18, 55–68.
Norton, T. T., & Godwin, D. W. (1992). Inhibitory GABAergic
control of visual signals at the lateral geniculate nucleus. Progress
in Brain Research, 90, 193–217.
Orban, G., Kato, H., & Bishop, P. O. (1979). End-zone region in
receptive field of hypercomplex and other striate neurons in the
cat. Journal of Neurophysiology, 42, 818–832.
Orban, G., Kato, H., & Bishop, P. O. (1979). Dimensions and
properties of end-zone inhibitory areas in receptive fields of
hypercomplex cells in cat striate cortex. Journal of Neurophysiol-
ogy, 42, 833–849.
Peterhans, E., & von der Heydt, R. (1989). Mechanisms of contour
perception in monkey visual cortex 2: contours bridging gaps.
Journal of Neuroscience, 9, 1749–1763.
Pettigrew, J. D., & Daniels, J. D. (1973). Gamma-aminobutyric acid
antagonism in visual cortex: different effects on simple, complex,
and hypercomplex neurons. Science, 182, 81–83.
Rose, D., & Blakemore, C. (1974). Effects of bicuculline on functions
of inhibition in visual cortex. Nature, 249, 375–377.
Saito, H., Tanaka, K., Fukada, Y., & Oyamada, H. (1988). Analysis
of discontinuity in visual contours in area 19 of the cat. Journal of
Neuroscience, 8, 1131–1143.
Shimojo, S., Silverman, G. H., & Nakayama, K. (1989). Occlusion
and the solution to the aperture problem for motion. Vision
Research, 29, 619–626.
Shimojo, S., & Nakayama, K. (1990). Amodal representation of
occluded surfaces: role of invisible stimuli in apparent motion
correspondence. Perception, 19, 285–299.
Sillito, A. M. (1975). The contribution of inhibitory mechanisms to
the receptive field properties of neurones in the striate cortex of
the cat. Journal of Physiology (London), 250, 305–329.
Sillito, A. M. (1992). GABA mediated inhibitory processes in the
function of the geniculo-striate system. Progress in Brain Re-
search, 90, 349–384.
Smith, G. B., & Olsen, R. W. (1995). Functional domains of GABAA
receptors. Trends in Pharmacological Sciences, 16, 162–168.
Somers, D. C., Nelson, S. B., & Sur, M. (1995). An emergent model
of orientation selectivity in cat visual cortical simple cells. Journal
of Neuroscience, 15, 5448–5465.
Stoner, G. R., Albright, T. D., & Ramachandran, V. S. (1990).
Transparency and coherence in human motion perception. Na-
ture, 344, 153–155.
Stoner, G. R., & Albright, T. D. (1992). Neural correlates of percep-
tual motion coherence. Nature, 358, 412–414.
Tanaka, K., Ohzawa, I., Ramoa, A. S., & Freeman, R. D. (1987).
Receptive field properties of cells in area 19 of the cat. Experimen-
tal Brain Research, 65, 549–558.
von der Heydt, R., & Peterhans, E. (1989). Mechanisms of contour
perception in monkey visual cortex 1: lines of pattern discontinu-
ities. Journal of Neuroscience, 9, 1731–1748.
.
